The global antacids market is expected to be worth USD 6,971.2 million by the end of 2023 and further expand at a CAGR of 4.9% to reach a valuation of USD 11,194.8 million by 2033.
According to a recent study by Future Market Insights, proton pump inhibitors are leading the market with a share of about 25.8% in the year 2022 within the global market.
Growth in the industry could be attributed to an increase in conditions like heartburn and GERD. The demand for over-the-counter digestive products to treat gastrointestinal disorders is rising as a result of the expanding trend toward self-medication.
| Attribute | Details |
|---|---|
| Antacids Market Size, 2022 | USD 6,646.9 million |
| Antacids Market Size, 2023 | USD 6,971.2 million |
| Antacids Market Size, 2033 | USD 11,194.8 million |
| Value CAGR (2023 to 2033) | 4.9% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
An Increase in the Geriatric Population
Globally, the geriatric population is increasing rapidly, leading to an increase in various clinical conditions like acidity problems. For instance, report published by Economics and Social Affairs, 2020, globally, there were 727 million people 65 years of age or older in 2020. By 2050, it is anticipated that this number will have more than doubled, reaching over 1.5 billion people.
Symptomatic disorders like oesophageal cancer and Barrett's esophagus are relatively common in such people. To cure these diseases, a combination of therapies is implemented, and antacid use in these cases has significantly increased, likely to fuel market expansion throughout the projection period.
Factors Restraining Demand for Antacids
Antacids frequently cause milk-alkali syndrome and dose-dependent rebound hyperacidity as side effects. The detrimental impact of antacids containing aluminum hydroxide cause aluminum poisoning, constipation, osteomalacia, and hypophosphatemia. It is projected that the increasing concerns about these harmful side effects slow the expansion of the market.
Antacids also cause the absorption of other acid-reducing medications when taken with them, which reduces their effectiveness.
The antacids market recorded a growth of around 4.7% and reached a valuation of USD 6,646.9 million in 2022. The sale of antacids expanded owing to cases of heartburn, gastric ulcers, and ingestion.
| Antacids Market Size, 2022 | USD 6,646.9 million |
|---|
New drugs that support the market's expansion are being developed by researchers. Eminent market participants make significant contributions to drug development and discovery.
Thus, owing to the factors mentioned above, the global market is expected to grow at a rate of 4.9% during the forecast period from 2023 to 2033
| Countries | Market Share |
|---|---|
| United States | 28.1% |
| China | 6.1% |
| India | 4.5% |
| Germany | 6.2% |
| United Kingdom | 5.2% |
The United States holds around 28.1% share of the global market and is projected for continued profitable growth.
The prevalence of gastrointestinal issues is on the rise, and antacid products are becoming widely known among consumers in the United States. However, the availability of effective treatment options and the presence of numerous manufacturers in the United States market has made this one of the key areas in the antacid market.
For instance, in a report published by the Centers for Disease Control and Prevention on 13 September 2021, in the United States, there are 8 million visits to emergency departments when digestive issues are the primary diagnosis as of 2019.
China is set to exhibit a growth rate of nearly 6.1% over the forecast period due to the rise in the geriatric population and the extensive utilization of antacids to relieve GERD-related issues.
One of the world's fastest-growing aging populations is in China. For instance, records stated by the World Health Organization (WHO), By 2040, it is anticipated that 28% of China's population will be over 60. A significant increase in the country's geriatric population has led to China experiencing substantial growth in the artificial tears market.
India is set to exhibit a CAGR of nearly 4.3% globally, with a market share of 4.5% in 2022.
In India, substantial financing and the launch of several healthcare programs, like Pradhan Mantri Jan Arogya Yojana and Ayushman Bharat, which offer accessible healthcare facilities and reimbursement options to patients receiving healthcare treatment, are boosting the demand for the market.
Increasing disposable income in middle-class families enables them to spend more money on their healthcare expenditure to get high-quality treatment facilities. The pharmaceutical sector has continuously seen lucrative growth in the Research and Development sector.
| By Drug Class | Market Share |
|---|---|
| Proton Pump Inhibitors | 25.3% |
| H2 Antagonist | 21% |
| Acid Neutralizers | 18.5% |
| Pro-Motility Agents | 8% |
| Anti-H.Pyrolic Drugs | 13.7% |
| Prostaglandin Analogous | 10.3% |
| Others | 3.3% |
Proton pump inhibitors are expected to present high growth at a CAGR of 4.5% by the end of the forecast period, with a market share of 25.3% by the end of 2022. Proton pump inhibitors are a class of medication that reduces the amount of stomach acid produced by glands in the lining of the stomach. Furthermore, it reduces the effects of acid reflux on the lower esophagus.
Tablets hold a market share of 25.5% in 2022 and are expected to display gradual growth over the forecast period, with an estimated CAGR of 4.4% by 2033.
Tablets are the easiest way to consume the drug, and it is safe. To treat indigestion and heartburn, antacids work by neutralizing the acid in your stomach. Tablets of antacids cure indigestion and heartburn and work by neutralizing the acid in the stomach
The oral route of administration usage is more as compared to injectables. Oral holds a prominent market share of 64.4% during the year 2022, a CAGR of 4.7% by the end of the forecast period. Owing to its advantages, such as patient compliance, non-invasiveness, and convenience of drug administration, the oral route of administration is the most favored method.
Gastroesophageal reflux disease holds a market share of 49.2% in 2022 and is expected to display gradual growth over the forecast period, with an estimated CAGR of 4.7% in 2033.
When stomach acid repeatedly flows back into the tube between the stomach and mouth, it causes gastroesophageal reflux disease. The rising cases of typical GERD symptoms include heartburn, so it holds a prominent position in the market segment.
Retail pharmacies held a prominent market share of 44.0% in 2022, with a CAGR of 4.4% in the forecast period. The prominent market share is expected to be held by retail pharmacies.
This is primarily due to the continuing higher dependency on pharmacies, dominant fragment, propelling sales of the overall market. Retail pharmacy stores hold a variety of products of different brands and can be easily located near the residential area, hence gaining the prominent position in the distribution channel based on the share of the market.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The market for the production of antacids is fragmented, with several competitors. These businesses are employing strategies including collaborations, partnerships, mergers and acquisitions, and new drug releases to satisfy consumer demand and increase their client base.
Recent Development
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | USD million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, Israel, South Africa and North Africa |
| Key Market Segments Covered | Drug Class, Dosage Form, Route of Administration, Indication, Distribution Channel and Region |
| Key Companies Profiled | Johnson and Johnson; Sanofi S.A.; Bayer AG; Sun Pharmaceuticals Ltd; Zydus Lifesciences; Abbott Laboratories; AstraZeneca plc; Boehringer Ingelheim International GmbH; Dr. Reddy’s Laboratories Ltd.; GlaxoSmithKline plc; Pfizer Inc.; Procter & Gamble Company; Reckitt Benckiser Group PLC; Takeda Pharmaceutical Company Limited.; F. Hoffmann-La Roche Ltd; Mylan N.V; Hikma Pharmaceuticals PLC; Teva Pharmaceutical Industries Ltd.; Bristol Myers Squibb Company; Novartis AG; Lupin; Cipla Inc; Aurobindo Pharma; Fresenius Kabi AG; Alkem Labs. |
| Pricing | Available upon Request |
The global antacids market was worth USD 6,646.9 million in 2022.
The rising prevalence of gastric diseases, growing cases of heartburn, and gastric ulcers.
The United States, China, India, Germany, and the United Kingdom are top countries.
The sales revenue of the antacids market is expected to register a 4.9% CAGR.
Johnson and Johnson, Sanofi S.A., Bayer AG, and Sun Pharmaceuticals Ltd are a few key players in the antacids industry.
The United States accounts for about 90.9% of the North American antacids market in 2022.
From 2017 to 2022, the market for antacids expanded at the rate of 3.5%.
India accounts for about 4.3% of market share in 2022 in the antacids market.
| Expected Market Value (2023) | USD 6 Billion |
|---|---|
| Anticipated Forecast Value (2033) | USD 12 Billion |
| Projected Growth Rate (2023 to 2033) | 7.2% |
| Market Size Value in 2022 | USD 816.8 million |
|---|---|
| Market Forecast Value in 2032 | USD 1,435.4 million |
| Global Growth Rate (2022 to 2032) | 5.8% CAGR |
Explore Therapy Area Insights
View Reports
Antacids Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
